Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Depemokimab in ABPA With Severe Eosinophilic Asthma
NCT07828327Not yet recruiting
- Sponsor
- Shandong Provincial Qianfoshan Hospital
- Start
- Nov 2026
- Primary completion
- Feb 2027
- Countries
- 1
01
Overview
Open-label, single-arm trial of depemokimab in allergic bronchopulmonary aspergillosis (ABPA) and eosinophilic asthma (EA), sponsored by Shandong Provincial Qianfoshan Hospital. Primary endpoint: Number of steroid requiring exacerbations at 26 weeks. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
depemokimab
03
Conditions
allergic bronchopulmonary aspergillosis (ABPA)eosinophilic asthma (EA)
Beyond the preview
Go deeper on NCT07828327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07828327.